

April 28, 2015

National Stock Exchange of India Limited
Listing Department, Exchange Plaza
Bandr Kurla Complex, Bandra (East)
Mumbai – 400 051

Fax No. 022- 26598237 / 38

NSE Symbol – WOCKPHARMA

Dear Sir,

During the last US FDA cGMP inspection of the facilities at L1- Chikalthana and Waluj in Aurangabad, Maharashtra, some observations were reported pertaining to batches of some products manufactured prior to the US FDA Import Alerts.

Whereas the Company continues to supply some of the products in the US market manufactured in the same facilities, several batches of other products, manufactured prior to the Import Alerts may still be in the US market.

As a measure of preparedness and as an abundant precaution, the Company has now decided to recall, as a part of remedial measure all the remaining batches in the US market that were manufactured prior to the US FDA Import Alerts even though there is no evidence of risk to patient safety from the products currently available in the US market.

Additionally, the MHRA, UK has restored the EU GMP certification of our potent product facility at Kadaiya, Daman.

As per clause 36 of the Listing Agreement the company keeps the exchange informed about events, information etc. including price sensitive information in accordance with regulatory requirement.

This is for your information and record.

Yours Cordially,

For Wockhardt Limited



Amruta Avasare
Assistant Company Secretary